Market Currents
The Street's Adam Feuerstein wonders whether AstraZeneca's (AZN) and Nektar's (NKTR) critical...
-
Tuesday, November 13, 2012, 9:33 AM ETThe Street's Adam Feuerstein wonders whether AstraZeneca's (AZN) and Nektar's (NKTR) critical naloxegol product for opioid-induced constipation failed one of its Phase III trials rather than passed it, as the companies indicate. Feuerstein's skepticism is based on AZN retrieving data from one patient that was thought to be non-retrievable after the database for the trial had been locked.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
This news story has 1 comment:
Disclaimer: I am not invested in AZN in any way. It's on my watchlist, waiting for a lower entry price... and this little b*tch's stories might just give me that chance.